In diffuse large B cell lymphoma (DLBCL) with EZH2Y641 mutation, treatment with an EZH2 inhibitor reduced H3K27me3 in the promoter region of NLRC5, resulting in increased NLRC5 and MHC-I expression [34]. Here, NLRC5 is linked to diffuse large B-cell lymphoma.